Skip to main content
. Author manuscript; available in PMC: 2011 Jan 20.
Published in final edited form as: J Am Chem Soc. 2010 Jan 20;132(2):798–806. doi: 10.1021/ja908544f

Table 1.

Summary of Spectral and Inhibition Data obtained for 1 and 3-8

R Ki (μM) Fe3+ type Fe3+ Ks (μM)a Fe2+ type Fe2+ Ks (μM)
Imidazole -- 29.7 ± 0.8 II 120 ± 20 I N/D
L-Nitroarginine NHNO2 0.9 ± 0.2 I 1.07 ± 0.01 I N/D
1 CH2SCH3 5.9 ± 0.4 I 2.2 ± 0.2 I N/D
3 (CH2)2SCH2CH3 33 ± 2 II 34 ± 2 II 15.5 ± 0.1
4 CH2SCH2CH3 8.6 ± 0.9 I 15 ± 3 II 8 ± 1
5 (CH2)3SCH3 32 ± 4 I 170 ± 10 N/D N/D
6 CH3S(CH2)2CH3 59 ± 4 I 550 ± 50 II 22 ± 2
7 (CH2)2S(CH2)2CH3 >500 I 1940 ± 90 II 110. ± 9
8 (CH2)2SCH(CH3)2 >500 I / II 1010 ± 40b II 77 ± 8
a

For type I inhibitors, “actual Ks” values are shown, converted from apparent Ks based on the concentration of imidazole used.32

b

This is the type I Ks value, i.e., from titration of imidazole—nNOS.

All values are reported as the mean ± the standard deviation of 2-3 experiments.